Real-Life Effectiveness and Safety of Baricitinib in Patients with Severe Alopecia Areata: A 24-Week Italian Study

September 2024 in “ Journal of the European Academy of Dermatology and Venereology ”

Bianca Maria Piraccini, Francesca Pampaloni, Stephano Cedirian, Federico Quadrelli, Francesca Bruni, Luca Rapparini, Gemma Caro, Maria Cristina Acri, Lorenzo Ala, Alfredo Rossi, Giovanni Pellacani, Francesco Lacarrubba, Giuseppe Micali, Federica DallʼOglio, Maria Vastarella, Mariateresa Cantelli, Paola Nappa, Laura Diluvio, L. Bianchi, Laura Gnesotto, Andrea Sechi, Luigi Naldi, F. Tassone, K. Peris, Giacomo Caldarola, L. M. Pinto, Giampiero Girolomoni, Federico Marangoni, Francesco Bellinato, Paolo Gisondi, Ilaria Scandagli, Francesca Prignano, Nicola Pimpinelli, Carlo Tomasini, Stefania Barruscotti, Edoardo De Simoni, Oriana Simonetti, Francesca Ambrogio, Caterina Foti, Valeria Boccaletti, Alessandro Fraghì, Angelo Valerio Marzano, Maria A. Mattioli, La Rocca, Mattia Barbareschi, Silvia Ferrucci, Giuseppe Gallo, Simone Ribero, Pietro Quaglino, Riccardo Balestri, Tommaso Ioris, Raffaele Dante Caposiena, Iris Zalaudek, Emanuele Vagnozzi, Maria Concetta Fargnoli, Chiara Caponio, Pietro Rubegni, Élisa Cinotti, Emanuele Trovato, M. Romanelli, Valentina Dini, Flavia Manzo Margiotta, Claudio Feliciani, Maria Beatrice De Felici Del Giudice, Laura Atzori, Silvia Sanna, Serena Lembo, Annunziata Raimondo, Michela Magnano, Michela Starace

baricitinib alopecia areata SALT score trichoscopy yellow dots black dots

TLDR Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.

The study assessed the effectiveness and safety of baricitinib in treating severe alopecia areata over 24 weeks in 118 Italian patients. Results showed significant hair regrowth, with 70% achieving a 50% improvement in the SALT score. The mean SALT score decreased from 96.6 to 48, with 42.3% achieving SALT 30, 31.3% achieving SALT 20, and 20.3% achieving SALT 10. Mild adverse events were reported in 12.7% of patients, with no drop-outs. The study supports baricitinib as a promising treatment for severe alopecia areata, especially in early stages, and recommends trichoscopy for early response detection.

View this study on onlinelibrary.wiley.com →

Discuss this study in the Community →

Research cited in this study

8 / 8 results

Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials

research Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials

September 2023 in “British Journal of Dermatology”

Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.

Scalp Hair Regrowth Is Associated With Improvements in Health-Related Quality of Life and Psychological Symptoms in Patients With Severe Alopecia Areata: Results From Two Randomized Controlled Trials

research Scalp Hair Regrowth Is Associated With Improvements in Health-Related Quality of Life and Psychological Symptoms in Patients With Severe Alopecia Areata: Results From Two Randomized Controlled Trials

3 citations , June 2023 in “Journal of dermatological treatment”

Regrowing scalp hair improves quality of life and reduces anxiety and depression in severe alopecia areata patients.

research Baricitinib for the Treatment of Alopecia Areata

6 citations , May 2023 in “Drugs”

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

research Adverse Events in Patients Treated With Jak-Inhibitors for Alopecia Areata: A Systematic Review

2 citations , April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

research Two Phase 3 Trials of Baricitinib for Alopecia Areata

148 citations , March 2022 in “The New England Journal of Medicine”

Baricitinib was effective in treating alopecia areata in two major trials.

research Alopecia Areata: An Update on Etiopathogenesis, Diagnosis, and Management

290 citations , August 2021 in “Clinical Reviews in Allergy & Immunology”

JAK inhibitors show promise for treating alopecia areata, but more research is needed.

research Common Causes of Hair Loss: Clinical Manifestations, Trichoscopy, and Therapy

47 citations , December 2020 in “Journal of the European Academy of Dermatology and Venereology”

The document concludes that understanding and treating hair loss requires recognizing its various types and using appropriate diagnostic tools and treatments.

research Italian Guidelines in Diagnosis and Treatment of Alopecia Areata

37 citations , December 2019 in “Giornale italiano di dermatologia e venereologia”

The Italian guidelines offer advice for diagnosing and treating alopecia areata based on expert opinion and limited clinical trial evidence.

Related Community Posts Join

6 / 14 results

Compressed part of research of theory of androgenic/anabolitic balance. AGA h-responders analytic. Theory of physio-metabolitic method of anti AGA treatment

community Compressed part of research of theory of androgenic/anabolitic balance. AGA h-responders analytic. Theory of physio-metabolitic method of anti AGA treatment

in Research 865 upvotes 1 year ago

The treatment for androgenetic alopecia involves using finasteride and minoxidil with intense exercise and cold exposure to boost metabolism and reduce androgenic effects, potentially leading to hair regrowth. This approach may activate biological pathways for improved hair and overall health.

community What are the odds baricitinib will get a topical otc version for androgenic alopecia?

in Research/Science 2 years ago

Baricitinib, approved for alopecia areata, might be considered for treating receding hairlines. The discussion is about the possibility of an over-the-counter topical version for androgenic alopecia.

community Lilly to seek first approval of an autoimmune drug for hair loss

in Research/Science 20 upvotes 4 years ago

Eli Lilly's drug baricitinib showed effectiveness in treating alopecia areata, with higher doses resulting in significant hair regrowth compared to placebo. The treatment is not for male pattern baldness.

community Anyone else taking Litfulo (ritlecitinib) to treat their alopecia?

in Treatment 7 upvotes 2 years ago

A user diagnosed with Alopecia Areata started using Litfulo (ritlecitinib), kenalog shots, and mometasone furoate 0.1%. They shaved their head and are seeking others' experiences with Litfulo.

community I am a dermatologist with a clinical interest in alopecia. AMA

in Will treatment work for me? 3 years ago

In this conversation, 4990 discussed various treatments for hair loss, including oral minoxidil, PRP, transplan, Jak inhibitors, Dutasteride, Finasteride, Olumiant, Ketoconazole, RU58841, microneedling, baricitinib, and CCCA. They recommended scalp biopsies in unclear cases of DUPA, twice weekly to twice daily shampooing for topical minoxidil users, and two sessions spaced one month apart with follow up at month three to determine the effectiveness of PRP treatment.

community Olumiant active ingredient Baricitinib

in Research/Science 1 upvotes 2 years ago

The conversation is about someone inquiring if anyone has tried Olumiant or its active ingredient, Baricitinib, for hair loss, mentioning the cost and that they have ordered Baricitinib.

Related Research

3 / 3 results

research Alopecia Areata: A Multifactorial Autoimmune Condition

148 citations , December 2018 in “Journal of autoimmunity”

Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.

research Linear Alopecia Areata

4 citations , November 2018 in “JAAD case reports”

Alopecia areata can sometimes appear as a straight line of hair loss instead of round patches.

research Treating Resistant Cases of Alopecia Universalis

May 2018 in “Journal of cosmetology & trichology”

Combining platelet-rich plasma therapy with prostaglandin-F eye drops can significantly regrow hair in alopecia universalis.